 |
인쇄하기
취소
|
Handok teams up with AmpliMed over promising anticancer drug
Handok Pharm announced on September 5 that it has entered into a licensing agreement with the U.S. company AmpliMed for Amplimexon(imexon, inj.), a lead compound for treatment of various cancers.
Under the terms of the agreement, Handok will have an exclusive license to develop and market Amplimexon in Korea.
Amplimexon is a small molecule belonging to a class of compounds known as cyanoa...
Under the terms of the agreement, Handok will have an exclusive license to develop and market Amplimexon in Korea.
Amplimexon is a small molecule belonging to a class of compounds known as cyanoa...
Fees
- Email service daily and homepage access.
- $300 per month.
- 5 Email holders per each company.
- Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.